Brodalumab in the Treatment of Immune-Related Adverse Events
for
Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer,
Location: New York NY
Sponsor: Brian Henick, MD
Sex: All
Age: 18+
Code: NCT06673329
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
By submitting, you consent to the use of your personal details, including contact information and location, to respond to your request for information related to clinical trials, as outlined in the Privacy Policy. If at any time you want to discontinue receiving alerts, please click the Unsubscribe link in the email received.
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer